Mussa Banisadre, MD
Hematology · Modesto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
- Since medical school
- 53 years
- Graduated 1973
Offices
3 locations · Stockton Hematology Oncology Medical Group Inc · 9 clinicians in this group
Looking this up.
Hospitals listed: Adventist Health Sonora · Doctors Medical Center · Emanuel Medical Center · Memorial Medical Center · Oak Valley Hospital District. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Banisadre’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A38740 · Current
Licensed to practise in California · since 1982 · expires 2028-02-29 · Shiraz University Faculty of Medicine Aka Pahlavi University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health SonoraSonora, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative wound dehiscence rate: 3.5 (2.04 to 4.96) · 288 cases, Jul 2022 – Jun 2024Worse than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 1.3 (1 to 1.6) · 1,004 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- Doctors Medical CenterModesto, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.02 to 1.71), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.35 (0.81 to 1.9) · 6,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.281, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.326, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.183, Oct 2024 – Sep 2025
- Emanuel Medical CenterTurlock, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.231, Oct 2024 – Sep 2025
- Memorial Medical CenterModesto, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.093, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Oak Valley Hospital DistrictOakdale, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Adventist Health Sonora
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative wound dehiscence rateComplications and deaths | 3.5 (2.04 to 4.96) · 288 cases | Worse | Jul 2022 – Jun 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 1,004 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.14 to 2.16) · 582 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.5 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.91 (123.44 to 242.37) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,364 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,671 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,602 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.24 to 5.59) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.98 to 4.2) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.97 (0 to 16.16) · 306 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.72 (1.85 to 9.58) · 277 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.06) · 2,750 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.614 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -23.8 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.4 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 381 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.3 to 8.1) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (9.1 to 14.7) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.3) · 1,835 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Doctors Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 3 the same, 1 worse of 6 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.02 to 1.71) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.35 (0.81 to 1.9) · 6,296 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.281 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.326 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.183 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.31 to 2.23) · 1,396 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 183.31 (147.26 to 219.36) · 127 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4.1 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.1 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.2 · 276 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.8 · 321 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 364 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.9 · 767 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 3,719 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,050 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,169 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.12 (2.19 to 6.06) · 1,622 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.3) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.23 to 4.04) · 1,601 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.79 (5.73 to 23.85) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (0.75 to 9.23) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.9 · 67 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.484 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.582 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 424 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24 · 682 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 36.6 · 326 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 70.5 · 378 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 366 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 564 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 70 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.7 · 120 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.4) · 573 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.7) · 303 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,045 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 57% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Emanuel Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.231 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.94) · 622 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.46 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.82 (131.99 to 239.65) · 55 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 10.8 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 287 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 365 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 443 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 1,680 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 4,151 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.53 (1.2 to 5.87) · 700 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.43) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.04) · 3,326 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 45 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.908 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.836 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.997 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 307 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 461 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -12.8 · 290 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.8 · 417 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 37.9 · 472 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 524 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.9 to 7.6) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (7.4 to 12.8) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.5 to 19.3) · 257 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 289 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 14% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.093 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.41 to 2.2) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.75 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.77 (144.66 to 226.88) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.1 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 513 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 640 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 4,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.42) · 10,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 10,422 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.58 to 5.23) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.45 to 3.38) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.1 (1.78 to 4.42) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.71 (5.69 to 17.72) · 885 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.28 (3.75 to 10.81) · 829 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.72) · 9,080 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 283 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.389 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.485 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.507 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 849 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 19.2 · 201 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.4 · 584 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.6 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 895 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.9) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 273 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 341 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (10.2 to 16.1) · 2,334 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 717 cases | No different | Jan 2024 – Dec 2024 |
What patients said (655 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Oak Valley Hospital District
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 0 better, 2 the same, 2 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.47 to 1.48) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 19.1 · 41 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 122 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 387 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.49) · 391 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.58 (0 to 1.88) · 243 cases | No different | Jul 2022 – Jun 2024 |
| Hospital return days for heart failure patientsUnplanned return visits | 113.4 · 27 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 48.3 · 47 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.5 to 17.7) · 186 cases | No different | Jan 2022 – Dec 2024 |
Original Medicare doctor bills
$1,124,159
Medicare paid this office $1,124,159 for 293 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 252 | $46,265 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $20,480 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $5,019 | $21 |
| New patient visit (60+ min) | 25 | $3,868 | $155 |
| Short return visit (20+ min) | 47 | $3,570 | $55 |
See all 17 services
| Return visit (30+ min) | 252 | $46,265 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $20,480 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $5,019 | $21 |
| New patient visit (60+ min) | 25 | $3,868 | $155 |
| Short return visit (20+ min) | 47 | $3,570 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $3,392 | $46 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $3,080 | $44 |
| Injection of additional new drug or substance into vein | 27 | $2,869 | $11 |
| Long return visit (40+ min) | 17 | $2,253 | $133 |
| Administration of chemotherapy into vein, each additional hour | 19 | $1,757 | $19 |
| New patient visit (45+ min) | 17 | $1,398 | $82 |
| Injection of drug or substance under skin or into muscle | 22 | $1,206 | $10 |
| Irrigation of implanted venous access drug delivery device | 19 | $1,167 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $900 | $14 |
| Injection, palonosetron hcl, 25 mcg | 17 | $720 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $127 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $64 | None |
Who their Medicare patients are
293 Original Medicare patients in 2024. Average age 76 · Women 70% · Also on Medicaid 10% · Health risk score 1.36. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 75% · Cancer 59% · Diabetes 32% · Chronic kidney disease 24% · Coronary heart disease 19% · Atrial fibrillation 19% · Heart failure 13% · COPD 13% · Depression 12% · Stroke 6%.
The office billed $4,355,685, Medicare allowed $1,429,747 and paid $1,124,159; for 66,362 services of 92 kinds; $1,007,291 of it was for drugs given in the office and $116,868 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 293 | 66,362 | 76 | 1.36 | $4,355,685 | $1,124,159 |
| 2023 | 286 | 74,037 | 75 | 1.42 | $3,754,570 | $650,965 |
| 2022 | 262 | 23,405 | 76 | 1.43 | $1,130,420 | $290,314 |
| 2021 | 256 | 26,243 | 75 | 1.49 | $1,286,515 | $315,069 |
| 2020 | 268 | 50,594 | 75 | 1.63 | $2,153,671 | $534,392 |
| 2019 | 437 | 52,308 | 75 | 1.78 | $1,509,270 | $511,486 |
| 2018 | 505 | 64,745 | 75 | 1.66 | $2,305,942 | $937,952 |
| 2017 | 543 | 60,545 | 75 | 1.69 | $2,584,566 | $1,025,778 |
| 2016 | 512 | 69,083 | 76 | 1.75 | $2,803,789 | $1,067,023 |
| 2015 | 516 | 53,963 | 76 | 1.74 | $2,696,211 | $1,047,609 |
| 2014 | 478 | 93,460 | 76 | 1.68 | $2,418,796 | $962,368 |
| 2013 | 480 | 52,171 | 76 | 1.54 | $1,974,696 | $739,946 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Return visit (30+ min) | 236 | $52,262 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $21,856 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $6,009 | $24 |
| Short return visit (20+ min) | 51 | $5,131 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $3,719 | $54 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $3,684 | $54 |
| Long return visit (40+ min) | 20 | $3,413 | $142 |
| Injection of additional new drug or substance into vein | 26 | $2,773 | $13 |
| New patient visit (45+ min) | 18 | $2,422 | $135 |
| New patient visit (60+ min) | 13 | $2,306 | $177 |
| Injection of drug or substance under skin or into muscle | 28 | $2,281 | $12 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,140 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $1,817 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,659 | $138 |
| Injection, palonosetron hcl, 25 mcg | 20 | $832 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $799 | $20 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 14 | $229 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $184 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $81 | None |
2022: 7 services
| Return visit (30+ min) | 240 | $53,323 | $96 |
| New patient visit (60+ min) | 39 | $6,680 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,445 | $82 |
| Long return visit (40+ min) | 14 | $2,230 | $149 |
| Injection of drug or substance under skin or into muscle | 17 | $702 | $12 |
| Infusion, normal saline solution, 250 cc | 24 | $89 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 14 | $31 | None |
2021: 11 services
| Return visit (30+ min) | 229 | $49,895 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $9,496 | $123 |
| New patient visit (60+ min) | 28 | $4,996 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $3,513 | $27 |
| Short return visit (20+ min) | 25 | $2,168 | $57 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $2,166 | $18 |
| Irrigation of implanted venous access drug delivery device | 16 | $1,314 | $19 |
| Infusion, normal saline solution, 250 cc | 33 | $288 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $142 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 12 | $132 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 21 | $60 | None |
2020: 18 services
| Return visit (30+ min) | 237 | $53,594 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 25 | $18,890 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $7,222 | $58 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $6,377 | $59 |
| New patient visit (60+ min) | 33 | $5,402 | $164 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 19 | $4,364 | $26 |
| Short return visit (20+ min) | 36 | $3,047 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $2,941 | $18 |
| Administration of chemotherapy into vein, each additional hour | 15 | $2,914 | $26 |
| Irrigation of implanted venous access drug delivery device | 17 | $1,899 | $22 |
| Long return visit (40+ min) | 15 | $1,807 | $120 |
| Injection of additional new drug or substance into vein | 16 | $1,171 | $14 |
| Injection of drug or substance under skin or into muscle | 12 | $615 | $11 |
| Infusion, normal saline solution, 250 cc | 48 | $492 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 28 | $336 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $196 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 21 | $166 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $34 | None |
2019: 22 services
| Return visit (30+ min) | 247 | $49,184 | $80 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $19,701 | $120 |
| Return visit (30+ min) | 141 | $13,072 | $54 |
| New patient visit (60+ min) | 34 | $5,472 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $4,485 | $26 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $4,312 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $4,211 | $61 |
| Short return visit (20+ min) | 35 | $2,708 | $48 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 23 | $2,377 | $18 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,186 | $59 |
| Administration of chemotherapy into vein, each additional hour | 16 | $2,177 | $26 |
| Irrigation of implanted venous access drug delivery device | 22 | $2,062 | $20 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,483 | $78 |
| Injection of additional new drug or substance into vein | 21 | $1,419 | $14 |
| Short return visit (20+ min) | 31 | $1,357 | $34 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 32 | $1,289 | None |
| Injection, carboplatin, 50 mg | 13 | $897 | None |
| Injection of drug or substance under skin or into muscle | 17 | $774 | $13 |
| Infusion, normal saline solution, 250 cc | 55 | $400 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 25 | $277 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $152 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $48 | None |
2018: 23 services
| Return visit (30+ min) | 388 | $63,893 | $65 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $33,615 | None |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $20,032 | $113 |
| Return visit (30+ min) | 113 | $9,608 | $62 |
| Short return visit (20+ min) | 114 | $8,436 | $42 |
| New patient visit (60+ min) | 57 | $7,923 | $139 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 23 | $4,372 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $4,120 | $54 |
| Administration of chemotherapy into vein, each additional hour | 15 | $3,733 | $25 |
| Injection of drug or substance under skin or into muscle | 26 | $2,320 | $16 |
| Irrigation of implanted venous access drug delivery device | 25 | $2,231 | $18 |
| Injection of additional new drug or substance into vein | 22 | $1,974 | $14 |
| Long return visit (40+ min) | 20 | $1,965 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,718 | $55 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,684 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $1,678 | $16 |
| Short return visit (20+ min) | 32 | $1,327 | $40 |
| Injection, carboplatin, 50 mg | 12 | $1,072 | None |
| Infusion, normal saline solution, 250 cc | 55 | $411 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $207 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 21 | $155 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $89 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $47 | None |
2017: 23 services
| Return visit (30+ min) | 441 | $95,272 | $77 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $31,967 | None |
| Administration of chemotherapy into vein, 1 hour or less | 35 | $26,375 | $116 |
| Short return visit (20+ min) | 174 | $15,049 | $53 |
| New patient visit (60+ min) | 67 | $10,832 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $4,804 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $4,551 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $4,346 | $55 |
| Injection of additional new drug or substance into vein | 25 | $3,561 | $18 |
| Administration of chemotherapy into vein, each additional hour | 15 | $3,299 | $24 |
| Long return visit (40+ min) | 28 | $3,191 | $114 |
| Injection of drug or substance under skin or into muscle | 25 | $2,597 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $2,503 | $56 |
| Irrigation of implanted venous access drug delivery device | 24 | $2,498 | $18 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $2,041 | $82 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 21 | $2,031 | $17 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,204 | $24 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 13 | $717 | None |
| Infusion, normal saline solution, 250 cc | 68 | $433 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $200 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $186 | $9 |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $142 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $63 | None |
2016: 24 services
| Return visit (30+ min) | 387 | $70,346 | $74 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 18 | $50,895 | None |
| Administration of chemotherapy into vein, 1 hour or less | 32 | $23,998 | $112 |
| Return visit (30+ min) | 136 | $13,624 | $55 |
| New patient visit (60+ min) | 57 | $8,495 | $149 |
| Short return visit (20+ min) | 94 | $7,689 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $6,258 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $3,770 | $52 |
| Injection of drug or substance under skin or into muscle | 32 | $3,429 | $21 |
| New patient visit (60+ min) | 25 | $3,296 | $132 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $3,070 | $56 |
| Administration of chemotherapy into vein, each additional hour | 19 | $3,053 | $23 |
| Short return visit (20+ min) | 49 | $2,650 | $38 |
| Injection of additional new drug or substance into vein | 25 | $2,588 | $18 |
| Irrigation of implanted venous access drug delivery device | 27 | $2,466 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 21 | $2,238 | $17 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,234 | $57 |
| Long return visit (40+ min) | 16 | $1,677 | $105 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $880 | $80 |
| Infusion, normal saline solution, 250 cc | 60 | $354 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 11 | $295 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $270 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $169 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $39 | None |
2015: 29 services
| Return visit (30+ min) | 246 | $61,733 | $83 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $38,565 | None |
| Return visit (30+ min) | 173 | $30,402 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $24,658 | $114 |
| Infusion into a vein for hydration, 31-60 minutes | 50 | $13,878 | $47 |
| Short return visit (20+ min) | 83 | $8,272 | $54 |
| Short return visit (20+ min) | 106 | $8,181 | $39 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $7,402 | $53 |
| New patient visit (60+ min) | 44 | $7,055 | $160 |
| New patient visit (60+ min) | 50 | $6,760 | $135 |
| Injection of additional new drug or substance into vein | 41 | $5,916 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $5,804 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $4,648 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $4,646 | $59 |
| Administration of chemotherapy into vein, each additional hour | 24 | $3,570 | $24 |
| Injection of drug or substance under skin or into muscle | 34 | $3,079 | $21 |
| Injection, carboplatin, 50 mg | 18 | $2,117 | None |
| Irrigation of implanted venous access drug delivery device | 21 | $2,064 | $20 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,558 | $82 |
| Long return visit (40+ min) | 17 | $1,455 | $86 |
| Long return visit (40+ min) | 11 | $1,311 | $119 |
| Infusion, normal saline solution, 250 cc | 66 | $360 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 37 | $253 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 15 | $248 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $213 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 14 | $134 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $90 | $8 |
| Injection, paclitaxel, 1 mg | 14 | $86 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 29 | $50 | None |
2014: 31 services
| Return visit (30+ min) | 231 | $58,105 | $81 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 14 | $34,905 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $29,005 | None |
| Return visit (30+ min) | 159 | $27,323 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 34 | $25,722 | $110 |
| Infusion into a vein for hydration, 31-60 minutes | 42 | $16,760 | $47 |
| Short return visit (20+ min) | 103 | $7,894 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $6,884 | $25 |
| Injection of additional new drug or substance into vein | 36 | $6,799 | $19 |
| Short return visit (20+ min) | 69 | $6,727 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $6,629 | $58 |
| New patient visit (60+ min) | 43 | $5,845 | $136 |
| Administration of additional new drug or substance into vein, 1 hour or less | 19 | $5,606 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $5,424 | $56 |
| Injection of drug or substance under skin or into muscle | 35 | $4,640 | $20 |
| New patient visit (60+ min) | 22 | $3,602 | $164 |
| Administration of chemotherapy into vein, each additional hour | 22 | $2,977 | $23 |
| Irrigation of implanted venous access drug delivery device | 20 | $2,268 | $20 |
| Long return visit (40+ min) | 20 | $1,879 | $89 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,301 | $81 |
| Injection, carboplatin, 50 mg | 11 | $1,241 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 27 | $467 | None |
| Infusion into a vein for hydration, each additional hour | 14 | $463 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 34 | $344 | None |
| Infusion, normal saline solution, 250 cc | 56 | $327 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $263 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $112 | $7 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 11 | $105 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $50 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $48 | None |
| Ringers lactate infusion, up to 1000 cc | 12 | $34 | None |
2013: 28 services
| Return visit (30+ min) | 247 | $58,007 | $80 |
| Return visit (30+ min) | 156 | $29,713 | $59 |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $26,678 | $118 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $23,082 | None |
| Infusion into a vein for hydration, 31-60 minutes | 49 | $15,480 | $49 |
| Short return visit (20+ min) | 81 | $8,713 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $7,735 | $56 |
| New patient visit (60+ min) | 54 | $7,021 | $130 |
| New patient visit (60+ min) | 40 | $6,379 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $6,290 | $27 |
| Injection of additional new drug or substance into vein | 40 | $6,268 | $19 |
| Short return visit (20+ min) | 74 | $5,182 | $38 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $4,838 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $4,020 | $60 |
| Injection of drug or substance under skin or into muscle | 31 | $3,707 | $21 |
| Administration of chemotherapy into vein, each additional hour | 25 | $3,185 | $26 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 30 | $2,771 | $79 |
| Irrigation of implanted venous access drug delivery device | 23 | $2,643 | $20 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 39 | $1,773 | None |
| Long return visit (40+ min) | 17 | $1,464 | $77 |
| Injection, carboplatin, 50 mg | 15 | $1,020 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 37 | $450 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $383 | $13 |
| Infusion, normal saline solution, 250 cc | 58 | $215 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $169 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 14 | $147 | None |
| Insertion of needle into vein for collection of blood sample | 14 | $66 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $48 | None |
Drugs they prescribed that Part D paid
$2,295,486
Pharmacies billed $2,295,486 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (65 of 1,381) in 2024. Above the middle of the specialty; the typical hematology clinician is at 4%.
1,178 generic and 203 brand-name prescriptions · $2,295,486 in drug cost · 24 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 43 | $657,075 | $15,281 |
| Brukinsa | 20 | $271,337 | $13,567 |
| Lenalidomide | 25 | $264,249 | $10,570 |
| Kisqali | 13 | $220,024 | $16,925 |
| Tagrisso | 11 | $173,719 | $15,793 |
See all 29 drugs
| Revlimid | 43 | $657,075 | $15,281 |
| Brukinsa | 20 | $271,337 | $13,567 |
| Lenalidomide | 25 | $264,249 | $10,570 |
| Kisqali | 13 | $220,024 | $16,925 |
| Tagrisso | 11 | $173,719 | $15,793 |
| Venclexta | 12 | $54,010 | $4,501 |
| Eliquis | 19 | $11,527 | $607 |
| Imatinib Mesylate | 36 | $10,857 | $302 |
| Exemestane | 22 | $5,352 | $243 |
| Letrozole | 196 | $4,906 | $25 |
| Tamoxifen Citrate | 124 | $3,499 | $28 |
| Anastrozole | 98 | $2,366 | $24 |
| Hydroxyurea | 67 | $2,012 | $30 |
| Dexamethasone | 76 | $733 | $10 |
| Oxycodone-Acetaminophen | 17 | $711 | $42 |
| Hydrocodone-Acetaminophen | 34 | $674 | $20 |
| Ondansetron Odt | 23 | $408 | $18 |
| Ondansetron | 33 | $376 | $11 |
| Lidocaine-Prilocaine | 21 | $226 | $11 |
| Levothyroxine | 25 | $223 | $9 |
| Gabapentin | 23 | $219 | $10 |
| Prochlorperazine Maleate | 19 | $206 | $11 |
| Prednisone | 37 | $190 | $5 |
| Allopurinol | 14 | $132 | $9 |
| Furosemide | 27 | $132 | $5 |
| Potassium Chloride | 13 | $117 | $9 |
| Acyclovir | 16 | $113 | $7 |
| Folic Acid | 11 | $68 | $6 |
| Diazepam | 20 | $32 | $2 |
Year by year
| 2024 | 1,381 | 279 | 5% (65) | 15% | $2,295,486 |
| 2023 | 1,519 | 308 | 7% (112) | None | $1,738,578 |
| 2022 | 1,392 | 266 | 5% (70) | 15% | $2,034,077 |
| 2021 | 1,615 | 273 | 5% (75) | 17% | $2,162,040 |
| 2020 | 1,252 | 235 | 4% (49) | 15% | $1,528,915 |
| 2019 | 1,579 | 288 | 3% (47) | None | $2,455,864 |
| 2018 | 1,656 | 318 | 4% (71) | 16% | $1,720,217 |
| 2017 | 1,594 | 299 | 6% (93) | 19% | $2,097,280 |
| 2016 | 1,541 | 258 | 7% (111) | None | $1,293,965 |
| 2015 | 1,632 | 267 | 8% (130) | None | $1,444,559 |
| 2014 | 1,566 | 263 | 8% (132) | None | $977,550 |
| 2013 | 1,430 | 232 | 7% (93) | None | $733,810 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Revlimid | 33 | $566,308 | $17,161 |
| Kisqali | 12 | $195,129 | $16,261 |
| Imbruvica | 11 | $176,283 | $16,026 |
| Lenalidomide | 11 | $168,956 | $15,360 |
| Abiraterone Acetate | 11 | $23,360 | $2,124 |
| Eliquis | 24 | $13,930 | $580 |
| Imatinib Mesylate | 39 | $12,819 | $329 |
| Letrozole | 255 | $11,075 | $43 |
| Tamoxifen Citrate | 118 | $7,521 | $64 |
| Anastrozole | 128 | $4,153 | $32 |
| Hydroxyurea | 81 | $3,424 | $42 |
| Hydrocodone-Acetaminophen | 77 | $1,811 | $24 |
| Ondansetron | 72 | $1,683 | $23 |
| Dexamethasone | 60 | $1,077 | $18 |
| Ondansetron Odt | 22 | $1,063 | $48 |
| Oxycodone-Acetaminophen | 17 | $768 | $45 |
| Prednisone | 72 | $664 | $9 |
| Potassium Chloride | 23 | $362 | $16 |
| Levothyroxine | 21 | $298 | $14 |
| Bicalutamide | 13 | $234 | $18 |
| Lidocaine-Prilocaine | 11 | $212 | $19 |
| Lorazepam | 25 | $205 | $8 |
| Sulfamethoxazole-Trimethoprim | 17 | $178 | $10 |
| Amitriptyline | 16 | $148 | $9 |
| Furosemide | 34 | $141 | $4 |
| Allopurinol | 20 | $124 | $6 |
| Gabapentin | 13 | $116 | $9 |
| Diazepam | 14 | $53 | $4 |
2022: 31 drugs
| Revlimid | 56 | $972,229 | $17,361 |
| Imbruvica | 17 | $253,950 | $14,938 |
| Xtandi | 14 | $183,205 | $13,086 |
| Eliquis | 40 | $24,074 | $602 |
| Abiraterone Acetate | 28 | $22,727 | $812 |
| Imatinib Mesylate | 29 | $10,640 | $367 |
| Letrozole | 221 | $7,126 | $32 |
| Tamoxifen Citrate | 95 | $5,931 | $62 |
| Anastrozole | 133 | $4,677 | $35 |
| Hydroxyurea | 51 | $2,281 | $45 |
| Hydrocodone-Acetaminophen | 53 | $1,778 | $34 |
| Ondansetron | 51 | $1,548 | $30 |
| Megestrol Acetate | 13 | $973 | $75 |
| Dexamethasone | 40 | $960 | $24 |
| Prednisone | 92 | $887 | $10 |
| Ondansetron Odt | 12 | $750 | $63 |
| Fentanyl | 11 | $495 | $45 |
| Bicalutamide | 16 | $361 | $23 |
| Diphenoxylate-Atropine | 13 | $345 | $27 |
| Potassium Chloride | 20 | $287 | $14 |
| Allopurinol | 24 | $236 | $10 |
| Temazepam | 14 | $227 | $16 |
| Lorazepam | 30 | $191 | $6 |
| Furosemide | 33 | $191 | $6 |
| Gabapentin | 24 | $186 | $8 |
| Levothyroxine | 18 | $176 | $10 |
| Amitriptyline | 12 | $160 | $13 |
| Baclofen | 14 | $128 | $9 |
| Tamsulosin | 11 | $110 | $10 |
| Alprazolam | 12 | $80 | $7 |
| Hydrochlorothiazide | 14 | $41 | $3 |
2021: 32 drugs
| Revlimid | 41 | $697,652 | $17,016 |
| Jakafi | 19 | $308,425 | $16,233 |
| Imbruvica | 15 | $220,348 | $14,690 |
| Remicade | 12 | $114,918 | $9,576 |
| Eliquis | 39 | $19,041 | $488 |
| Abiraterone Acetate | 18 | $17,136 | $952 |
| Imatinib Mesylate | 27 | $13,874 | $514 |
| Letrozole | 221 | $6,168 | $28 |
| Tamoxifen Citrate | 101 | $5,985 | $59 |
| Anastrozole | 163 | $4,626 | $28 |
| Hydroxyurea | 53 | $2,126 | $40 |
| Hydrocodone-Acetaminophen | 62 | $2,047 | $33 |
| Ondansetron | 55 | $1,537 | $28 |
| Potassium Chloride | 21 | $1,453 | $69 |
| Dexamethasone | 42 | $1,228 | $29 |
| Leucovorin | 11 | $1,197 | $109 |
| Allopurinol | 46 | $636 | $14 |
| Prednisone | 72 | $573 | $8 |
| Diphenoxylate-Atropine | 20 | $504 | $25 |
| Levothyroxine | 23 | $404 | $18 |
| Fluorouracil | 17 | $384 | $23 |
| Gabapentin | 32 | $358 | $11 |
| Temazepam | 30 | $196 | $7 |
| Acyclovir | 21 | $184 | $9 |
| Doxorubicin | 13 | $148 | $11 |
| Furosemide | 25 | $136 | $5 |
| Alprazolam | 30 | $135 | $4 |
| Amitriptyline | 11 | $134 | $12 |
| Lorazepam | 23 | $117 | $5 |
| Tamsulosin | 22 | $105 | $5 |
| Ciprofloxacin | 12 | $91 | $8 |
| Hydrochlorothiazide | 15 | $47 | $3 |
2020: 29 drugs
| Revlimid | 51 | $723,511 | $14,186 |
| Jakafi | 18 | $250,918 | $13,940 |
| Remicade | 13 | $124,494 | $9,576 |
| Velcade | 11 | $70,656 | $6,423 |
| Imbruvica | 12 | $70,379 | $5,865 |
| Abiraterone Acetate | 31 | $41,752 | $1,347 |
| Imatinib Mesylate | 24 | $23,556 | $982 |
| Xarelto | 13 | $10,811 | $832 |
| Tamoxifen Citrate | 105 | $4,925 | $47 |
| Anastrozole | 182 | $4,579 | $25 |
| Letrozole | 136 | $3,517 | $26 |
| Hydroxyurea | 48 | $1,576 | $33 |
| Hydrocodone-Acetaminophen | 44 | $1,544 | $35 |
| Dexamethasone | 54 | $1,520 | $28 |
| Ondansetron | 42 | $1,170 | $28 |
| Methylprednisolone | 13 | $748 | $58 |
| Prednisone | 61 | $551 | $9 |
| Levothyroxine | 22 | $499 | $23 |
| Gabapentin | 34 | $360 | $11 |
| Acyclovir | 21 | $305 | $15 |
| Potassium Chloride | 17 | $295 | $17 |
| Diphenoxylate-Atropine | 11 | $275 | $25 |
| Allopurinol | 29 | $264 | $9 |
| Amitriptyline | 16 | $255 | $16 |
| Lorazepam | 34 | $220 | $6 |
| Temazepam | 16 | $131 | $8 |
| Furosemide | 23 | $125 | $5 |
| Alprazolam | 15 | $121 | $8 |
| Metoclopramide | 13 | $42 | $3 |
2019: 32 drugs
| Revlimid | 62 | $886,036 | $14,291 |
| Jakafi | 30 | $403,188 | $13,440 |
| Opdivo | 24 | $220,188 | $9,174 |
| Remicade | 13 | $124,494 | $9,576 |
| Imbruvica | 11 | $105,617 | $9,602 |
| Velcade | 12 | $77,079 | $6,423 |
| Rituxan | 14 | $71,975 | $5,141 |
| Abiraterone Acetate | 11 | $26,329 | $2,394 |
| Xarelto | 13 | $14,053 | $1,081 |
| Tamoxifen Citrate | 101 | $4,097 | $41 |
| Anastrozole | 173 | $3,188 | $18 |
| Letrozole | 161 | $3,021 | $19 |
| Ondansetron | 63 | $2,759 | $44 |
| Hydroxyurea | 79 | $2,422 | $31 |
| Dexamethasone | 74 | $1,920 | $26 |
| Raloxifene | 13 | $1,227 | $94 |
| Hydrocodone-Acetaminophen | 25 | $1,121 | $45 |
| Gabapentin | 51 | $1,093 | $21 |
| Bicalutamide | 18 | $621 | $35 |
| Prednisone | 60 | $442 | $7 |
| Levothyroxine | 19 | $431 | $23 |
| Methylprednisolone | 11 | $311 | $28 |
| Allopurinol | 25 | $305 | $12 |
| Temazepam | 23 | $267 | $12 |
| Furosemide | 41 | $231 | $6 |
| Potassium Chloride | 16 | $229 | $14 |
| Alprazolam | 26 | $210 | $8 |
| Amitriptyline | 16 | $198 | $12 |
| Lansoprazole | 12 | $175 | $15 |
| Lorazepam | 22 | $108 | $5 |
| Metoclopramide | 12 | $99 | $8 |
| Sulfamethoxazole-Trimethoprim | 16 | $78 | $5 |
2018: 37 drugs
| Revlimid | 40 | $550,815 | $13,770 |
| Ibrance | 22 | $255,664 | $11,621 |
| Jakafi | 19 | $203,726 | $10,722 |
| Zytiga | 13 | $144,554 | $11,120 |
| Imatinib Mesylate | 38 | $86,532 | $2,277 |
| Imbruvica | 13 | $70,277 | $5,406 |
| Xarelto | 28 | $15,402 | $550 |
| Tamoxifen Citrate | 93 | $4,104 | $44 |
| Letrozole | 171 | $3,241 | $19 |
| Anastrozole | 185 | $3,193 | $17 |
| Hydroxyurea | 93 | $3,171 | $34 |
| Ondansetron | 92 | $2,726 | $30 |
| Gabapentin | 76 | $1,794 | $24 |
| Hydrocodone-Acetaminophen | 26 | $992 | $38 |
| Raloxifene | 16 | $915 | $57 |
| Oxycodone-Acetaminophen | 11 | $767 | $70 |
| Prednisone | 67 | $540 | $8 |
| Dexamethasone | 20 | $486 | $24 |
| Diphenoxylate-Atropine | 20 | $464 | $23 |
| Allopurinol | 22 | $379 | $17 |
| Levothyroxine | 14 | $283 | $20 |
| Warfarin | 13 | $272 | $21 |
| Megestrol Acetate | 12 | $252 | $21 |
| Alprazolam | 24 | $244 | $10 |
| Bicalutamide | 11 | $228 | $21 |
| Temazepam | 15 | $200 | $13 |
| Prochlorperazine Maleate | 15 | $174 | $12 |
| Amitriptyline | 14 | $173 | $12 |
| Pantoprazole | 13 | $163 | $13 |
| Acyclovir | 11 | $144 | $13 |
| Furosemide | 34 | $118 | $3 |
| Sulfamethoxazole-Trimethoprim | 14 | $97 | $7 |
| Lactulose | 12 | $85 | $7 |
| Fluconazole | 14 | $81 | $6 |
| Azithromycin | 12 | $80 | $7 |
| Lorazepam | 24 | $77 | $3 |
| Metoclopramide | 11 | $68 | $6 |
2017: 34 drugs
| Revlimid | 35 | $452,877 | $12,939 |
| Ibrance | 39 | $425,185 | $10,902 |
| Jakafi | 20 | $187,695 | $9,385 |
| Imatinib Mesylate | 36 | $156,634 | $4,351 |
| Imbruvica | 21 | $141,987 | $6,761 |
| Zytiga | 12 | $121,696 | $10,141 |
| Tarceva | 15 | $110,221 | $7,348 |
| Gleevec | 11 | $38,613 | $3,510 |
| Xarelto | 23 | $11,270 | $490 |
| Hydroxyurea | 97 | $3,320 | $34 |
| Letrozole | 188 | $3,024 | $16 |
| Tamoxifen Citrate | 56 | $2,824 | $50 |
| Exemestane | 11 | $2,700 | $245 |
| Anastrozole | 182 | $2,065 | $11 |
| Ondansetron | 89 | $1,958 | $22 |
| Morphine Sulfate Er | 14 | $1,377 | $98 |
| Hydrocodone-Acetaminophen | 42 | $1,291 | $31 |
| Raloxifene | 12 | $1,129 | $94 |
| Oxycodone-Acetaminophen | 15 | $886 | $59 |
| Bicalutamide | 21 | $874 | $42 |
| Allopurinol | 32 | $651 | $20 |
| Prednisone | 86 | $602 | $7 |
| Lidocaine-Prilocaine | 16 | $488 | $30 |
| Gabapentin | 31 | $305 | $10 |
| Temazepam | 20 | $277 | $14 |
| Warfarin | 15 | $235 | $16 |
| Dexamethasone | 21 | $154 | $7 |
| Alprazolam | 31 | $146 | $5 |
| Lorazepam | 37 | $140 | $4 |
| Pantoprazole | 12 | $126 | $10 |
| Furosemide | 29 | $101 | $3 |
| Amitriptyline | 12 | $94 | $8 |
| Sulfamethoxazole-Trimethoprim | 12 | $88 | $7 |
| Atenolol | 12 | $24 | $2 |
2016: 36 drugs
| Revlimid | 18 | $210,569 | $11,698 |
| Imatinib Mesylate | 31 | $209,162 | $6,747 |
| Jakafi | 21 | $188,621 | $8,982 |
| Zytiga | 12 | $103,627 | $8,636 |
| Gleevec | 13 | $103,111 | $7,932 |
| Avastin | 14 | $81,023 | $5,787 |
| Imbruvica | 11 | $66,747 | $6,068 |
| Exemestane | 11 | $4,792 | $436 |
| Oxycontin | 11 | $3,584 | $326 |
| Hydroxyurea | 98 | $2,860 | $29 |
| Letrozole | 146 | $2,400 | $16 |
| Anastrozole | 118 | $2,017 | $17 |
| Ondansetron | 99 | $1,964 | $20 |
| Hydrocodone-Acetaminophen | 33 | $1,811 | $55 |
| Tamoxifen Citrate | 71 | $1,793 | $25 |
| Morphine Sulfate Er | 13 | $1,362 | $105 |
| Bicalutamide | 23 | $1,019 | $44 |
| Prednisone | 76 | $515 | $7 |
| Allopurinol | 47 | $475 | $10 |
| Warfarin | 25 | $453 | $18 |
| Hydromorphone | 15 | $398 | $27 |
| Gabapentin | 17 | $308 | $18 |
| Dexamethasone | 36 | $299 | $8 |
| Lactulose | 20 | $281 | $14 |
| Levothyroxine | 12 | $253 | $21 |
| Acyclovir | 13 | $232 | $18 |
| Lorazepam | 39 | $218 | $6 |
| Alprazolam | 27 | $217 | $8 |
| Temazepam | 23 | $212 | $9 |
| Paroxetine | 16 | $197 | $12 |
| Lidocaine-Prilocaine | 11 | $190 | $17 |
| Potassium Chloride | 11 | $135 | $12 |
| Furosemide | 34 | $107 | $3 |
| Amitriptyline | 11 | $89 | $8 |
| Pantoprazole | 11 | $69 | $6 |
| Atenolol | 13 | $28 | $2 |
2015: 36 drugs
| Gleevec | 49 | $445,762 | $9,097 |
| Revlimid | 18 | $184,110 | $10,228 |
| Zytiga | 17 | $133,281 | $7,840 |
| Jakafi | 13 | $131,455 | $10,112 |
| Tarceva | 18 | $115,097 | $6,394 |
| Alimta | 24 | $90,270 | $3,761 |
| Enoxaparin | 14 | $10,196 | $728 |
| Oxycontin | 15 | $5,794 | $386 |
| Dronabinol | 17 | $5,599 | $329 |
| Hydroxyurea | 109 | $3,146 | $29 |
| Ondansetron | 98 | $2,905 | $30 |
| Hydrocodone-Acetaminophen | 51 | $2,419 | $47 |
| Tamoxifen Citrate | 80 | $2,362 | $30 |
| Carboplatin | 39 | $2,148 | $55 |
| Letrozole | 100 | $2,043 | $20 |
| Anastrozole | 111 | $1,936 | $17 |
| Octreotide Acetate | 11 | $1,477 | $134 |
| Duloxetine | 20 | $1,058 | $53 |
| Prednisone | 78 | $675 | $9 |
| Levothyroxine | 23 | $554 | $24 |
| Hydromorphone | 17 | $527 | $31 |
| Allopurinol | 50 | $475 | $9 |
| Lorazepam | 48 | $420 | $9 |
| Bethanechol Chloride | 11 | $419 | $38 |
| Alprazolam | 32 | $405 | $13 |
| Warfarin | 17 | $357 | $21 |
| Gabapentin | 17 | $308 | $18 |
| Dexamethasone | 38 | $301 | $8 |
| Bicalutamide | 11 | $228 | $21 |
| Temazepam | 32 | $217 | $7 |
| Lactulose | 17 | $197 | $12 |
| Furosemide | 53 | $177 | $3 |
| Paroxetine | 13 | $116 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $115 | $8 |
| Ciprofloxacin | 13 | $86 | $7 |
| Fluconazole | 12 | $80 | $7 |
2014: 34 drugs
| Revlimid | 28 | $266,522 | $9,519 |
| Gleevec | 27 | $200,676 | $7,432 |
| Zytiga | 16 | $129,468 | $8,092 |
| Tarceva | 15 | $78,761 | $5,251 |
| Alimta | 20 | $52,945 | $2,647 |
| Exemestane | 12 | $5,559 | $463 |
| Hydrocodone-Acetaminophen | 69 | $3,825 | $55 |
| Anastrozole | 128 | $3,395 | $27 |
| Lyrica | 14 | $2,613 | $187 |
| Hydroxyurea | 92 | $2,607 | $28 |
| Letrozole | 93 | $1,973 | $21 |
| Fentanyl | 17 | $1,954 | $115 |
| Ondansetron | 72 | $1,544 | $21 |
| Tamoxifen Citrate | 49 | $1,247 | $25 |
| Bicalutamide | 31 | $912 | $29 |
| Prednisone | 90 | $840 | $9 |
| Carboplatin | 19 | $727 | $38 |
| Allopurinol | 77 | $615 | $8 |
| Dexamethasone | 59 | $537 | $9 |
| Levothyroxine | 29 | $524 | $18 |
| Hydromorphone | 17 | $364 | $21 |
| Ondansetron Odt | 18 | $336 | $19 |
| Gabapentin | 15 | $332 | $22 |
| Potassium Chloride | 13 | $290 | $22 |
| Alprazolam | 28 | $282 | $10 |
| Temazepam | 30 | $274 | $9 |
| Lorazepam | 32 | $238 | $7 |
| Zolpidem | 15 | $164 | $11 |
| Warfarin | 15 | $161 | $11 |
| Lactulose | 14 | $150 | $11 |
| Sulfamethoxazole-Trimethoprim | 18 | $146 | $8 |
| Tamsulosin | 14 | $144 | $10 |
| Furosemide | 37 | $138 | $4 |
| Paroxetine | 13 | $89 | $7 |
2013: 34 drugs
| Gleevec | 23 | $159,722 | $6,944 |
| Revlimid | 16 | $145,867 | $9,117 |
| Tarceva | 15 | $98,050 | $6,537 |
| Alimta | 25 | $85,247 | $3,410 |
| Avastin | 15 | $59,360 | $3,957 |
| Gemcitabine | 16 | $8,137 | $509 |
| Anastrozole | 113 | $3,928 | $35 |
| Letrozole | 91 | $3,081 | $34 |
| Carboplatin | 45 | $2,721 | $60 |
| Celebrex | 13 | $2,564 | $197 |
| Hydroxyurea | 72 | $2,240 | $31 |
| Ondansetron | 81 | $1,933 | $24 |
| Hydrocodone-Acetaminophen | 50 | $1,634 | $33 |
| Morphine Sulfate Er | 12 | $1,454 | $121 |
| Tamoxifen Citrate | 82 | $1,431 | $17 |
| Gabapentin | 17 | $1,025 | $60 |
| Bicalutamide | 28 | $890 | $32 |
| Megestrol Acetate | 26 | $752 | $29 |
| Allopurinol | 92 | $572 | $6 |
| Dexamethasone | 42 | $455 | $11 |
| Lidocaine-Prilocaine | 13 | $367 | $28 |
| Prednisone | 54 | $309 | $6 |
| Lorazepam | 24 | $215 | $9 |
| Furosemide | 47 | $203 | $4 |
| Levothyroxine | 21 | $190 | $9 |
| Ibuprofen | 22 | $160 | $7 |
| Temazepam | 15 | $144 | $10 |
| Warfarin | 13 | $123 | $9 |
| Methadone | 12 | $118 | $10 |
| Paroxetine | 13 | $114 | $9 |
| Famotidine | 14 | $87 | $6 |
| Alprazolam | 15 | $75 | $5 |
| Zolpidem | 12 | $66 | $5 |
| Amitriptyline | 12 | $47 | $4 |
Money from drug and device companies
$2,902 in 2025
| 2025 | 21 | 78 | None | $2,902 |
| 2024 | 32 | 100 | None | $2,659 |
| 2023 | 33 | 87 | None | $2,283 |
| 2022 | 28 | 91 | None | $2,178 |
| 2021 | 28 | 124 | None | $2,968 |
| 2020 | 23 | 58 | None | $1,045 |
| 2019 | 29 | 110 | None | $1,941 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $1,315 | 19 payments
|
| Merck Sharp & Dohme | Keytruda | $301 | 11 payments
|
| Aveo Pharmaceuticals | Fotivda | $165 | 4 payments
|
| Janssen Biotech | Rybrevant | $150 | 5 payments
|
| Astellas Pharma US | Vyloy | $127 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $113 | 5 payments
|
See all 78 published payments
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-12-30 | Kisqali | $83 |
| SpringWorks Therapeutics | Meals · 2025-12-18 | Ogsiveo | $26 |
| Merck Sharp & Dohme | Meals · 2025-12-17 | Keytruda | $30 |
| SpringWorks Therapeutics | Meals · 2025-12-16 | Ogsiveo | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Opdivo | $23 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-11-26 | Kisqali | $83 |
| Astellas Pharma US | Meals · 2025-11-21 | Cresemba | $25 |
| Janssen Biotech | Meals · 2025-11-20 | Rybrevant | $1 |
| Janssen Biotech | Meals · 2025-11-20 | Rybrevant | $35 |
| Incyte | Meals · 2025-11-18 | Monjuvi | $24 |
| Merck Sharp & Dohme | Meals · 2025-11-13 | Keytruda | $33 |
| Array Biopharma | Meals · 2025-11-12 | Braftovi | $30 |
| Incyte | Meals · 2025-11-06 | Jakafi | $17 |
| Aveo Pharmaceuticals | Meals · 2025-11-05 | Fotivda | $32 |
| Janssen Biotech | Meals · 2025-10-30 | Rybrevant | $42 |
| Pfizer | Meals · 2025-10-28 | Xtandi | $24 |
| Novartis Pharmaceuticals | Meals · 2025-10-27 | Scemblix | $24 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-10-23 | Kisqali | $83 |
| Aveo Pharmaceuticals | Education · 2025-10-20 | Fotivda | $100 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-14 | Lynparza | $26 |
| GlaxoSmithKline | Meals · 2025-10-13 | Ojjaara | $15 |
| Stemline Therapeutics | Meals · 2025-10-10 | Orserdu | $35 |
| Merck Sharp & Dohme | Meals · 2025-09-24 | Keytruda | $30 |
| Janssen Biotech | Meals · 2025-09-23 | Rybrevant | $39 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-09-19 | Kisqali | $100 |
| Merck Sharp & Dohme | Meals · 2025-09-17 | Keytruda | $26 |
| Pfizer | Meals · 2025-08-26 | Elrexfio | $21 |
| Merck Sharp & Dohme | Meals · 2025-08-25 | Keytruda | $31 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $100 |
| Exelixis | Meals · 2025-08-19 | Cabometyx | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-15 | Enhertu | $28 |
| Tempus AI | Meals · 2025-08-13 | Xt Cdx | $26 |
| GlaxoSmithKline | Meals · 2025-08-12 | Ojjaara | $18 |
| SpringWorks Therapeutics | Meals · 2025-08-11 | Ogsiveo | $27 |
| Aveo Pharmaceuticals | Meals · 2025-08-06 | Fotivda | $3 |
| Aveo Pharmaceuticals | Meals · 2025-08-06 | Fotivda | $30 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-07-21 | Scemblix | $26 |
| Abbvie | Meals · 2025-07-17 | Imbruvica | $22 |
| Merck Sharp & Dohme | Meals · 2025-07-09 | Keytruda | $26 |
| Celgene | Meals · 2025-06-24 | Reblozyl | $24 |
| Merck Sharp & Dohme | Meals · 2025-06-17 | Keytruda | $29 |
| Novartis Pharmaceuticals | Meals · 2025-06-16 | Kisqali | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $100 |
| Astellas Pharma US | Meals · 2025-05-30 | Vyloy | $28 |
| Merck Sharp & Dohme | Meals · 2025-05-22 | Keytruda | $19 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-05-15 | Scemblix | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-14 | Opdivo | $30 |
| Astellas Pharma US | Education · 2025-04-30 | None | $75 |
| Eisai | Meals · 2025-04-29 | Lenvima | $18 |
| Merck Sharp & Dohme | Meals · 2025-04-28 | Keytruda | $21 |
| Abbvie | Meals · 2025-04-25 | Imbruvica | $30 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $100 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Lutathera | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Opdivo | $17 |
| Stemline Therapeutics | Meals · 2025-04-09 | Orserdu | $20 |
| Lilly USA | Meals · 2025-04-07 | Verzenio | $32 |
| Array Biopharma | Meals · 2025-03-31 | Lorbrena | $26 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $100 |
| Pfizer | Meals · 2025-03-25 | Elrexfio | $20 |
| Merck Sharp & Dohme | Meals · 2025-03-24 | Keytruda | $27 |
| Merck Sharp & Dohme | Meals · 2025-03-17 | Keytruda | $31 |
| Abbvie | Meals · 2025-03-10 | Epkinly | $18 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Scemblix | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-25 | Opdivo | $18 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $100 |
| Abbvie | Meals · 2025-02-20 | Imbruvica | $23 |
| Incyte | Meals · 2025-02-19 | Jakafi | $16 |
| Janssen Biotech | Meals · 2025-02-18 | Rybrevant | $33 |
| SpringWorks Therapeutics | Meals · 2025-02-12 | Ogsiveo | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-10 | Opdivo | $26 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-06 | Nubeqa | $20 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $100 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-13 | Enhertu | $19 |
| Biocon Biologics | Meals · 2025-01-09 | Fulphila | $29 |
| GlaxoSmithKline | Meals · 2025-01-08 | Ojjaara | $27 |
| Novartis Pharmaceuticals | Meals · 2025-01-06 | Fabhalta | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,659
| Novartis Pharmaceuticals | Kisqali | $590 | 16 payments
|
| Incyte | Monjuvi | $321 | 7 payments
|
| Abbvie | Venclexta | $222 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $165 | 7 payments
|
| Pfizer | Ibrance | $105 | 6 payments
|
| Merck Sharp & Dohme | Keytruda | $100 | 4 payments
|
| Janssen Biotech | Darzalex | $91 | 3 payments
|
| Celgene | Reblozyl | $89 | 4 payments
|
| Astellas Pharma US | Xtandi | $79 | 3 payments
|
| Daiichi Sankyo | Enhertu | $67 | 3 payments
|
| Genentech USA | Phesgo | $65 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $63 | 3 payments
|
| Stemline Therapeutics | Orserdu | $60 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $56 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $54 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $53 | 2 payments
|
| GlaxoSmithKline | Jemperli | $43 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $42 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $42 | 2 payments
|
| Genzyme | Sarclisa | $41 | 1 payment
|
| Array Biopharma | Lorbrena | $41 | 2 payments
|
| Eisai | Lenvima | $41 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $35 | 1 payment
|
| Sobi | Vonjo | $31 | 1 payment
|
| MorphoSys US | Monjuvi | $22 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $22 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $22 | 1 payment
|
| Azurity Pharmaceuticals | Vivimusta | $21 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $21 | 1 payment
|
| Celltrion USA | Vegzelma | $20 | 1 payment
|
| Mirati Therapeutics | Krazati | $17 | 1 payment
|
2023: $2,283
| Novartis Pharmaceuticals | Tasigna | $293 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $252 | 8 payments
|
| Seagen | Padcev | $211 | 3 payments
|
| Pfizer | Ibrance | $190 | 10 payments
|
| Kite Pharma | Yescarta | $169 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $142 | 6 payments
|
| Merck Sharp & Dohme | Keytruda | $133 | 7 payments
|
| Mirati Therapeutics | Krazati | $78 | 4 payments
|
| GlaxoSmithKline | Zejula | $61 | 3 payments
|
| Pharmacosmos Therapeutics | Monoferric | $59 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $56 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Epkinly | $53 | 3 payments
|
| Genentech USA | Tecentriq | $49 | 2 payments
|
| Janssen Biotech | Erleada | $42 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $39 | 2 payments
|
| Celgene | Reblozyl | $37 | 2 payments
|
| Array Biopharma | Lorbrena | $37 | 1 payment
|
| Octapharma USA | Panzyga | $33 | 1 payment
|
| EMD Serono | Bavencio | $29 | 1 payment
|
| Ipsen Biopharmaceuticals | Tazverik | $29 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $28 | 1 payment
|
| Incyte | Jakafi | $27 | 1 payment
|
| Taiho Oncology | Lonsurf | $26 | 1 payment
|
| MorphoSys US | Monjuvi | $25 | 1 payment
|
| Eisai | Lenvima | $24 | 1 payment
|
| Stemline Therapeutics | Orserdu | $24 | 1 payment
|
| PharmaEssentia USA | Besremi | $22 | 1 payment
|
| Foundation Medicine | None | $21 | 1 payment
|
| Amgen | Kyprolis | $21 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $20 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $20 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $19 | 1 payment
|
| Astellas Pharma US | Xtandi | $16 | 1 payment
|
2022: $2,178
| Novartis Pharmaceuticals | Kisqali | $552 | 16 payments
|
| GlaxoSmithKline | Zejula | $174 | 6 payments
|
| Amgen | Kyprolis | $173 | 6 payments
|
| AVEO Pharmaceuticals | Fotivda | $104 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $101 | 7 payments
|
| Celgene | Reblozyl | $100 | 5 payments
|
| Pfizer | Bosulif | $89 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $86 | 4 payments
|
| Abbvie | Venclexta | $85 | 3 payments
|
| Sobi | Doptelet | $80 | 3 payments
|
| Eisai | Lenvima | $76 | 4 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $68 | 3 payments
|
| Gilead Sciences | Trodelvy | $56 | 3 payments
|
| Genentech USA | Tecentriq | $54 | 2 payments
|
| Epizyme | Tazverik | $51 | 3 payments
|
| Kite Pharma | None | $50 | 3 payments
|
| Exelixis | Cabometyx | $43 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $36 | 1 payment
|
| Array Biopharma | Braftovi | $36 | 1 payment
|
| Seagen | Padcev | $35 | 2 payments
|
| Amneal Pharmaceuticals | Neupogen | $22 | 1 payment
|
| Janssen Biotech | Imbruvica | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $17 | 1 payment
|
| Taiho Oncology | Lonsurf | $16 | 1 payment
|
| EMD Serono | None | $16 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $13 | 1 payment
|
| Astellas Pharma US | Padcev | $12 | 1 payment
|
2021: $2,968
| Novartis Pharmaceuticals | Kisqali | $1,183 | 20 payments
|
| Amgen | Lumakras | $286 | 8 payments
|
| Eisai | Lenvima | $165 | 8 payments
|
| Seagen | Padcev | $143 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $132 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $118 | 6 payments
|
| Pfizer | Ibrance | $108 | 7 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $92 | 4 payments
|
| Janssen Biotech | Imbruvica | $79 | 4 payments
|
| GlaxoSmithKline | Zejula | $77 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $66 | 4 payments
|
| EMD Serono | None | $65 | 4 payments
|
| Kite Pharma | None | $58 | 3 payments
|
| Lilly USA | Cyramza | $50 | 3 payments
|
| MorphoSys US | Monjuvi | $46 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $45 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $39 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $24 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $23 | 1 payment
|
| Daiichi Sankyo | Enhertu | $22 | 1 payment
|
| AbbVie | Venclexta | $21 | 1 payment
|
| Celgene | Pomalyst | $20 | 1 payment
|
| Taiho Oncology | Inqovi | $19 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $19 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $18 | 1 payment
|
| Epizyme | Tazverik | $17 | 1 payment
|
| Array Biopharma | Braftovi | $14 | 1 payment
|
2020: $1,045
| Merck Sharp & Dohme | Keytruda | $110 | 6 payments
|
| Novartis Pharmaceuticals | Mekinist | $96 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $73 | 5 payments
|
| Celgene | Onureg | $69 | 4 payments
|
| Clovis Oncology | Rubraca | $63 | 3 payments
|
| Janssen Biotech | Imbruvica | $61 | 3 payments
|
| Eisai | Lenvima | $59 | 3 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $57 | 2 payments
|
| Genzyme | Elitek | $47 | 2 payments
|
| Kite Pharma | Yescarta | $47 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $46 | 3 payments
|
| Pfizer | Ibrance | $46 | 3 payments
|
| Kyowa Kirin | Sancuso | $44 | 3 payments
|
| Seagen | Padcev | $39 | 2 payments
|
| Genentech USA | Venclexta | $37 | 2 payments
|
| BeiGene USA | Brukinsa | $29 | 2 payments
|
| Amgen | Kyprolis | $23 | 1 payment
|
| AbbVie | Venclexta | $20 | 1 payment
|
| Taiho Oncology | Lonsurf | $19 | 1 payment
|
| Stemline Therapeutics | Elzonris | $19 | 1 payment
|
| Astellas Pharma US | Padcev | $17 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $13 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $12 | 1 payment
|
2019: $1,941
| Pfizer | Ibrance | $346 | 29 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $213 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $135 | 12 payments
|
| Amgen | Kyprolis | $124 | 5 payments
|
| AbbVie | Venclexta | $122 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $118 | 6 payments
|
| Eisai | Lenvima | $85 | 4 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $83 | 2 payments
|
| Genentech USA | Tecentriq | $73 | 4 payments
|
| Tesaro | Zejula | $62 | 2 payments
|
| Janssen Biotech | Imbruvica | $60 | 3 payments
|
| Genzyme | Libtayo | $57 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $54 | 3 payments
|
| Mylan Institutional | Fulphila | $54 | 3 payments
|
| Lilly USA | Cyramza | $52 | 3 payments
|
| Kyowa Kirin | Poteligeo | $51 | 4 payments
|
| Daiichi Sankyo | Injectafer | $40 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $30 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $28 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Seattle Genetics | None | $18 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $17 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $16 | 1 payment
|
| Taiho Oncology | Lonsurf | $15 | 1 payment
|
| Incyte | Jakafi | $13 | 1 payment
|
| Celgene | Revlimid | $12 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $12 | 1 payment
|
| Gilead Sciences | None | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1043264690
- Licence
- CA A38740California A38740: Current · expires 2028-02-29
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 1325 Melrose Ave, Suite A, Modesto, CA, 95350
- NPI first listed
- 2006-05-19
- NPI last updated
- 2008-04-14
This is when the NPI record was last certified, not a medical board exam.